ProMIS Neurosciences logo
PMNProMIS Neurosciences
Trade PMN now
ProMIS Neurosciences primary media

About ProMIS Neurosciences

ProMIS Neurosciences (TSX:PMN), (NASDAQ:PMN) focuses on discovering and developing treatments targeting neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease. This company aims to identify specific epitopes on misfolded proteins which are common in these conditions, leveraging their proprietary technology platforms to create both therapeutic and diagnostic solutions. Their portfolio includes several antibody candidates in preclinical development, designed to target toxic misfolded protein aggregates believed to contribute to the progression of neurodegenerative diseases. The ultimate objective of ProMIS Neurosciences is to halt disease progression and improve the quality of life for patients suffering from these devastating conditions.

What is PMN known for?

Snapshot

Public US
Ownership
2004
Year founded
7
Employees
Toronto, Canada
Head office
Loading Map...

Operations

All Locations
Toronto, CA

Produtos e/ou serviços de ProMIS Neurosciences

  • Development of precision medicine therapies targeting misfolded proteins implicated in neurodegenerative diseases like Alzheimer's and ALS.
  • Research on monoclonal antibodies targeting toxic oligomers for the treatment of ALS and Alzheimer's disease.
  • PMN310, an antibody therapy showing high selectivity for toxic amyloid-beta oligomers in Alzheimer's disease.
  • Collaboration with pharmaceutical companies to explore therapeutic antibodies for neurodegenerative diseases.
  • Diagnostic tools for early detection of biomarkers associated with neurodegenerative diseases.
  • Engagement in partnerships for the advancement of research and development in neurodegenerative disease therapies.

equipe executiva do ProMIS Neurosciences

  • Mr. Eugene W. WilliamsCo-Founder & Chairman
  • Mr. Neil K. Warma M.B.A.CEO, President, Compliance Officer & Director
  • Dr. Neil R. Cashman M.D.Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
  • Mr. Daniel E. Geffken M.B.A.Chief Financial Officer
  • Dr. Johanne Kaplan Ph.D.Chief Development Officer
  • Dr. David Wishart Ph.D.Chief Physics Officer
  • Mr. Dennis Chen Ph.D.Head of Manufacturing & Senior Consultant
  • Dr. Larry Douglas Altstiel M.D., Ph.D.Chief Medical Officer

Conecte-se conosco

A Grafa não é um consultor financeiro. Você deve buscar aconselhamento independente, jurídico, financeiro, tributário ou de outra natureza que se relacione às suas circunstâncias únicas.

A Grafa não se responsabiliza por qualquer perda causada, seja por negligência ou de outra forma, decorrente do uso ou da confiança nas informações fornecidas direta ou indiretamente pelo uso desta plataforma.